托法替布治疗类风湿关节炎一年对骨代谢的影响
托法替布临床有效并稳定骨密度,骨转换标志物显示骨形成增加、骨吸收减少的正平衡。
要点
- 托法替布治疗12个月可稳定类风湿关节炎患者的骨密度。
- 托法替布使骨转换标志物呈现正平衡:OC、OPG升高,CTX降低。
- 年龄、CRP、抗CCP和DKK-1影响托法替布对骨密度变化的效果。
核心结论
- 一年托法替布治疗稳定了类风湿关节炎患者的骨密度,并使骨转换标志物呈现正平衡。
主要发现
- 托法替布抑制DAS28、CRP和HAQ,临床有效,并减缓进一步骨丢失。
- 托法替布显著升高OC、OPG和维生素D3,降低CTX水平(p < 0.05)。
- 年龄及多个骨标志物(OC、CTX、P1NP、RANKL)与DXA测定的L2-4和股骨颈BMD呈负相关。
- CRP、DAS28和RANKL与QCT测定的体积BMD呈负相关。
- 年龄、CRP、抗CCP和DKK-1影响托法替布治疗对BMD变化的效果。
临床怎么用
- 对活动性类风湿关节炎患者,托法替布治疗可能有助于稳定骨密度并改善骨转换平衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Janus kinase (JAK) inhibitors are used to treat rheumatoid arthritis (RA). We assessed the effects of tofacitinib on bone density and bone markers in association with clinical and laboratory parameters in RA. Tofacitinib stabilized bone density and resulted in a positive balance of bone turnover. INTRODUCTION: Janus kinase (JAK) inhibitors emerged as new therapeutic options in rheumatoid arthritis (RA). We have little information on how it affects areal and volumetric bone mineral density (BMD) and bone turnover markers. The aim of this study was to assess the effects of 1-year tofacitinib therapy on bone metabolism in RA. METHODS: Thirty RA patients with active disease were treated with either 5 mg bid or 10 mg bid tofacitinib for 12 months. We determined DAS28, CRP, IgM rheumatoid factor (RF), and anti-cyclic citrullinated peptide (CCP) levels, as well as serum levels of sclerostin, osteocalcin (OC), P1NP, DKK-1, OPG, RANKL, and 25-hydroxy-vitamin D3. Areal and volumetric BMD were assessed by DXA and peripheral quantitative CT (QCT), respectively. RESULTS: Twenty-six patients (13 on each arm) completed the study. Tofacitinib was clinically effective by suppressing DAS28, CRP, and HAQ. This was accompanied by the attenuation of further bone loss. Tofacitinib therapy significantly increased OC, OPG, and vitamin D3, while decreased CTX levels (p < 0.05). Age and multiple bone markers (OC, CTX, P1NP, RANKL) inversely correlated with L2-4 and femoral neck BMD by DXA. CRP, DAS28, and RANKL inversely determined volumetric BMD by QCT. Age, CRP, anti-CCP, and DKK-1 influenced the effects of tofacitinib therapy on BMD changes. CONCLUSIONS: One-year tofacitinib treatment stabilized BMD in RA patients and resulted in a positive balance of bone turnover as indicated by bone biomarkers. Further studies are needed to evaluate the potential beneficial effects of JAK inhibitors on inflammatory bone loss.
引用
- Hamar A, Szekanecz Z, Pusztai A, et al. Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis. Osteoporos Int. 2021. PMID: 33559714. doi:10.1007/s00198-021-05871-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。